Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.

Evaluation of efficacy of Hydroxychloroquine as an add-on therapy to antithyroid drugs in the treatment of Graves disease: A Pilot study - Not Applicable

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054894

Enrollment

Registered

2023-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E050- Thyrotoxicosis with diffuse goiter

Interventions

Intervention1: hydroxychloroquine, carbimazole: Patients with newly diagnosed graveâ??s disease will be divided into two groups. One group of patients will be treated with a combination of hydroxychlo

Eligibility

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed Graveâ??s disease with serum total T4 levels more than 20 microgram/dl.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Patients on corticosteroids or immunosuppressive drugs 3. Patients in whom the use of hydroxychloroquine is contraindicated.

Design outcomes

Primary

Measure	Time frame
Remission of Graves disease asymptomatic with normalization of TFT & negative anti TSH receptor antibodies Time required for normalization of TFTTimepoint: 1 year	—

Secondary

Measure	Time frame
Reduction in clinical activity score in Graveâ??s disease patients with ophthalmopathyTimepoint: 1 year	—

Countries

India

Contacts

Public ContactD Venkateswarlu

Jawaharlal Nehru Medical College, Belagavi

victorvikrant@gmail.com9844445598

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026